Scribe Therapeutics

Engineering the future of genetic medicine

[Scribe Therapeutics @scribetx]

We're pleased to announce:

📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

[Scribe Therapeutics @scribetx]

Read the full report in our press release: https://t.co/skMsV7azli

@EASCongress #CRISPR #EpigeneticEditing #CVD

[Scribe Therapeutics @scribetx]

At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose.

Study highlights below ⬇️

[Scribe Therapeutics @scribetx]

#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic.

Thanks to @EASCongress for featuring it!

[Scribe Therapeutics @scribetx]

📰 @theheraldsun article: https://t.co/DNzkutZx7k

🎤 If you're at #EASCongress2026 on Monday, May 25, check out the late-breaking oral presentation by Scribe co-founder and CEO @BenjaminLOakes, highlighting our preclinical data for STX-1150: https://t.co/mApxYNLX4c

@EASCongress

[Scribe Therapeutics @scribetx]

In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️

[Scribe Therapeutics @scribetx]

More details on our clinical trial and commentary from Scribe CEO @BenjaminLOakes and Principal Investigator Stephen Nicholls (@MonashVHI, Victorian Heart Hospital, @MonashUni, @MonashHealth):

https://t.co/mApxYNLX4c

#CVD #HeartHealth #CRISPR #EpigeneticEditing

[Scribe Therapeutics @scribetx]

Announcing our first clinical trial.

Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD).

Details🧵

[Scribe Therapeutics @scribetx]

STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients.

Link to our full announcement below ❤️‍🩹

[Scribe Therapeutics @scribetx]

♥️ How our CRISPR by Design engineering approach integrates engineering of both the XE foundation to ELXR silencing machinery to enable Scribe’s lead cardiometabolic asset for LDL-C lowering

@ASGCTherapy #CRISPR #EpigeneticEditing #GeneEditing

[Scribe Therapeutics @scribetx]

At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing.

Highlights of our three oral presentations below and in thread 🧵

https://t.co/9YkjgQr8k5

[Scribe Therapeutics @scribetx]

🧬 Allosteric ELXR epigenetic silencers designed to improve specificity while still achieving potent and durable target repression

⚒️ XE gene editing engineering advancements, supported by mechanistic insights into guide potency and AI-enabled predictive modeling through DeepXE

[Scribe Therapeutics @scribetx]

Two #ASGCT26 oral presentations tomorrow!

🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors

[Scribe Therapeutics @scribetx]

Check out our full #ASGCT26 agenda for the week here: https://t.co/5DzF6sr0fs

[Scribe Therapeutics @scribetx]

We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation @BStaahl. Details below & more to come at @ASGCTherapy later this week!

🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability
🕒 May 11 at 3:07 pm ET

[Scribe Therapeutics @scribetx]

📊At #EASCongress2026, our late-breaker will report preclinical data for STX-1150, our PCSK9-targeting epigenetic silencing therapy for LDL-C lowering.

🔗 For more details, read our press release: https://t.co/5DzF6sr0fs

[Scribe Therapeutics @scribetx]

Next month, join us at the 2026 @ASGCTherapy Annual Meeting and @EASCongress !

[Scribe Therapeutics @scribetx]

🔬At #ASGCT2026, we'll be delivering 2 oral presentations and one workshop presentation featuring latest advances to our ELXR epigenetic silencing and X-Editor genome editing technologies, including DeepXE, our AI-enabled CRISPR design platform for predicting editing efficiency.